Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq(®) ) in children with severe haemophilia A: efficacy, safety and pharmacokinetics.
about
Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?Immunogenicity, efficacy and safety of Nuwiq(®) (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.PK-guided personalized prophylaxis with Nuwiq(®) (human-cl rhFVIII) in adults with severe haemophilia A.Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa).BAY 81-8973, a full-length recombinant factor VIII: manufacturing processes and product characteristics.Bioengineering coagulation factors for improved hemophilia treatments: Comment on: the mutation F309S increases FVIII secretion in human cell line.A close insight to factor VIII inhibitor in the congenital hemophilia A.Emerging drugs for the treatment of hemophilia A and B.Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.Production of recombinant coagulation factors: Are humans the best host cells?Current and emerging factor VIII replacement products for hemophilia A.Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.Successful perioperative haemostatic management of aortic coarctation in a 5-week-old infant with severe haemophilia A.Efficacy and safety of Nuwiq(®) (human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures.Simoctocog alfa for the treatment of hemophilia A.Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.Low incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A treated with octanate® : Final report from a prospective study.Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia.
P2860
Q33820925-1D20AA5A-C787-4696-A230-5D98F8028694Q38620816-0928A08F-FB88-4747-9B6E-FD33C512AE7FQ38705742-9B3E19DA-3E9A-43D9-A05B-07DA242290A5Q38720560-B2F49241-803D-4DC0-AB01-417B6BC91A4DQ38725317-53274605-6131-481D-A8C2-C5B57F8FA66CQ38752057-A32C1628-B2B2-4227-A3E7-A39065083FF9Q38883211-A73BB688-6958-4C96-AA6D-A6A0F3FA2E41Q38933707-7ED09490-50B9-4A9F-822A-56CD15AA5B3AQ38944642-DA06B31A-767F-40DE-A70B-A1FA3D3E59F9Q39170433-5463A340-EC67-41F1-8863-4CBDACF78928Q42375640-6B7F1996-A503-4367-AC9D-A615F7150FBBQ45864374-7D905C87-A004-4F4C-BC94-D4C9408A65BEQ45867867-A78F7B9F-B994-453C-A043-742B3B76073CQ45873356-1E82F0E1-73CE-462A-97BD-1B1F43B73F9BQ45873366-BB37B69D-21FF-4758-9209-70ECE2CA3A1DQ45874491-809A07F8-AF03-4EF7-821B-30EB79F54E75Q47556737-2FE7CC9F-38A8-4DD0-93BD-9C6BC89FBD44Q55313906-C0C8907A-5CD9-41AC-9CB6-09DFD04CE81B
P2860
Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq(®) ) in children with severe haemophilia A: efficacy, safety and pharmacokinetics.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Novel, human cell line-derived ...... , safety and pharmacokinetics.
@en
type
label
Novel, human cell line-derived ...... , safety and pharmacokinetics.
@en
prefLabel
Novel, human cell line-derived ...... , safety and pharmacokinetics.
@en
P2093
P2860
P921
P356
P1433
P1476
Novel, human cell line-derived ...... y, safety and pharmacokinetics
@en
P2093
P2860
P304
P356
10.1111/HAE.12797
P577
2015-09-14T00:00:00Z